DrugPatentWatch Database Preview
Details for Patent: 10,047,117
Email this page to a colleague
» See Plans and PricingWhich drugs does patent 10,047,117 protect, and when does it expire?
Patent 10,047,117 protects OCALIVA and is included in one NDA.
This patent has sixty-three patent family members in nineteen countries.
Summary for Patent: 10,047,117
| Title: | Preparation and uses of obeticholic acid |
| Abstract: | The present invention relates to obeticholic acid: ##STR00001## or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid. |
| Inventor(s): | Steiner; Andre (Raubling, DE), Waenerlund Poulsen; Heidi (Koge, DK), Jolibois; Emilie (Cambridge, GB), Rewolinski; Melissa (San Diego, CA), Gross; Ralf (Raubling, DE), Sharp; Emma (Cambridge, GB), Dubas-Fisher; Fiona (Cambridge, GB), Eberlin; Alex (Cambridge, GB) |
| Assignee: | Intercept Pharmaceuticals, Inc. (New York, NY) |
| Application Number: | 14/947,658 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
Drugs Protected by US Patent 10,047,117
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | Start Trial | Start Trial | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) | Start Trial | ||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,047,117
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013277429 | Start Trial | |||
| Australia | 2016200832 | Start Trial | |||
| Australia | 2016375566 | Start Trial | |||
| Australia | 2017204057 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
